Predictive Oncology Inc.
POAI
Price:
$0.746
Market Cap:
$4.97M
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues...[Read more]
Industry
Medical - Instruments & Supplies
IPO Date
2010-05-03
Stock Exchange
NASDAQ
Ticker
POAI
PE Ratio
[-0.25]
ROE
[-303.92%]
Current Ratio
[1.20]
Dividend Yield
[0%]
Enterprise Value
[4.29M]
Dividend History
The ROE as of December 2024 (TTM) for Predictive Oncology Inc. (POAI) is -303.92%
According to Predictive Oncology Inc.’s latest financial reports and current stock price. The company's current ROE is -303.92%. This represents a change of 218.97% compared to the average of -95.28% of the last 4 quarters.
Predictive Oncology Inc. (POAI) Historical ROE (quarterly & annually)
How has POAI ROE performed in the past?
The mean historical ROE of Predictive Oncology Inc. over the last ten years is -2190.62%. The current -303.92% ROE has changed -86.13% with respect to the historical average. Over the past ten years (40 quarters), POAI's ROE was at its highest in in the December 2014 quarter at 42.88%. The ROE was at its lowest in in the September 2016 quarter at -9167.91%.
Average
-2190.62%
Median
-207.20%
Minimum
-18863.10%
Maximum
123.88%
Predictive Oncology Inc. (POAI) ROE by Quarter and Year
Discovering the peaks and valleys of Predictive Oncology Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 6.45%
Maximum Annual ROE = 123.88%
Minimum Annual Increase = -194.03%
Minimum Annual ROE = -18863.10%
| Year | ROE | Change |
|---|---|---|
| 2023 | -169.06% | 1.63% |
| 2022 | -166.35% | 240.75% |
| 2021 | -48.82% | -96.58% |
| 2020 | -1426.64% | 481.47% |
| 2019 | -245.35% | -98.70% |
| 2018 | -18863.10% | 6.45% |
| 2017 | -287.77% | -59.27% |
| 2016 | -706.52% | 506.55% |
| 2015 | -116.48% | -194.03% |
| 2014 | 123.88% | -57.61% |
Predictive Oncology Inc. (POAI) Average ROE
How has POAI ROE performed in the past?
The current ROE of Predictive Oncology Inc. (POAI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-128.07%
5-year avg
-411.24%
10-year avg
-2190.62%
Predictive Oncology Inc. (POAI) ROE vs. Peers
How is POAI’s ROE compared to its peers?
Predictive Oncology Inc.’s ROE is less than GlucoTrack, Inc. (1.63%), less than G Medical Innovations Holdings Ltd (208.58%), greater than Sharps Technology, Inc. (-110.41%), greater than Microbot Medical Inc. (-218.30%), greater than NEXGEL, Inc. (-76.97%), less than Pro-Dex, Inc. (16.74%), greater than Innovative Eyewear, Inc. (-24906.65%), less than Jin Medical International Ltd. (13.79%), greater than Bionano Genomics, Inc. (-176.27%), less than Intuitive Surgical, Inc. (15.59%), greater than Stereotaxis, Inc. (-115.14%), greater than Nyxoah S.A. (-51.64%), less than Daxor Corporation (10.04%), greater than Milestone Scientific Inc. (-60.26%),
| Company | ROE | Market cap |
|---|---|---|
| 1.63% | $4.14M | |
| 208.58% | $1.80M | |
| -110.41% | $3.61M | |
| -218.30% | $16.88M | |
| -76.97% | $32.19M | |
| 16.74% | $156.87M | |
| -24906.65% | $13.97M | |
| 13.79% | $153.42M | |
| -176.27% | $20.64M | |
| 15.59% | $191.28B | |
| -115.14% | $197.42M | |
| -51.64% | $274.88M | |
| 10.04% | $38.45M | |
| -60.26% | $65.43M |
Build a custom stock screener for Predictive Oncology Inc. (POAI) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Predictive Oncology Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Predictive Oncology Inc. (POAI) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Predictive Oncology Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Predictive Oncology Inc.'s ROE?
How is the ROE calculated for Predictive Oncology Inc. (POAI)?
What is the highest ROE for Predictive Oncology Inc. (POAI)?
What is the 3-year average ROE for Predictive Oncology Inc. (POAI)?
What is the 5-year average ROE for Predictive Oncology Inc. (POAI)?
How does the current ROE for Predictive Oncology Inc. (POAI) compare to its historical average?